Side effects of high-dose interferon therapy for chronic hepatitis C-Reference-Cited by-同舟云学术

Side effects of high-dose interferon therapy for chronic hepatitis C

Published:1996-09 Issue:3 Volume:25 Page:283-291
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Okanoue Takeshi,Sakamoto Shinichi,Itoh Yoshito,Minami Masahito,Yasui Koichiro,Sakamoto Masafumi,Nishioji Kenichi,Katagishi Tatsuo,Nakagawa Yoshihiro,Tada Hisashi,Sawa Yoshihiko,Mizuno Masayuki,Kagawa Keizo,Kashima Kei

Publisher

Elsevier BV

Subject

Hepatology

Reference43 articles.

1. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial;Davis;New Engl J Med,1989

2. A randomized, double-blind, placebo-controlled trial;Di Bisceglie;New Engl J Med,1989

3. Recombinant human α-interferon in patients with non-A, non-B hepatitis: a multicenter randomized controlled trial from France;Marcellin;Hepatology,1991

4. Thyroid autoimmunity in patients on long-term therapy with leukocyte-derived interferon;Burman;J Clin Endocrinol Metabol,1986

5. Psychiatric complications of long-term interferon alpha therapy;Renault;Arch Intern Med,1987

Cited by 407 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pegylated-interferon alpha (PEG-IFNα)-induced interstitial lung disease in a patient with chronic hepatitis B: A case report and literature review;Int. Journal of Clinical Pharmacology and Therapeutics;2024-08-01

2. Excessive Dynamic Airway Collapse After Entecavir Use in a Patient With Pegylated Interferon-Induced Undifferentiated Connective Tissue Disease and Entecavir Use to Prevent Hepatitis B Virus Reactivation Upon Giving Rituximab;Cureus;2024-06-21

3. Drug-induced hyperglycemia and diabetes;Therapies;2023-10

4. Cytokines and their role as immunotherapeutics and vaccine Adjuvants: The emerging concepts;Cytokine;2023-09

5. Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha;BMC Endocrine Disorders;2023-05-22